Randomized Trial on Effectiveness of ACTs in Ghana
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the effectiveness and safety of two Artemisinin Combination Therapies (ACTs) for the treatment of children with uncomplicated Plasmodium falciparum malaria
| Condition | Intervention | Phase |
|---|---|---|
|
Malaria, Falciparum |
Drug: Artesunate plus Amodiaquine Drug: Artemether-Lumefantrine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria |
- Clinical and PCR-controlled parasitological cure rate at day 28 [ Time Frame: 28 days ]
- Clinical and PCR-controlled parasitological cure rate at day 14 [ Time Frame: 14 days ]
- Effect on anaemia [ Time Frame: 28 days ]
- Molecular Drug Resistance Markers [ Time Frame: 28 days ]
- Recrudescence and Reinfection [ Time Frame: 28 days ]
- Effects on Gametocytemia [ Time Frame: 28 days ]
- Acceptance of Therapies [ Time Frame: 7 days ]
- Incidences of malaria episodes over a follow-up period of 1 year [ Time Frame: 12 months ]
| Enrollment: | 245 |
| Study Start Date: | September 2006 |
| Study Completion Date: | October 2007 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: AL
Artemether plus Lumefantrine 6 dose 3 days treatment
|
Drug: Artemether-Lumefantrine
Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
Other Name: Coartem®
|
|
Active Comparator: ASAQ
Artesunate plus Amodiaquine
|
Drug: Artesunate plus Amodiaquine
Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
Other Name: Arsucam®
|
Detailed Description:
Childhood mortality related to Plasmodium falciparum malaria is on the rise with more than 1 million deaths per year in Sub-Saharan Africa. In the context of growing drug-resistance to antimalarials health officials are calling for rapid replacement of failing drugs by combining antimalarial drugs. Artemisinin Combination Antimalarial Therapies (ACTs) are in the focus of malaria control programmes and are recommended for first-line treatment in African countries. ACTs have been reported to be highly effective as artemisinin derivatives cause a rapid and substantial decrease in the parasite load when used for treating patients with malaria and resistance to artemisinin is still lacking. However, the short half-lives of artemisinins result in frequent recrudescent infections when used alone and therefore, much interest lays on the choice of the combination partner drug. ACTs also have been proposed as a means of reducing transmission by the reduction of gametocytes and of delaying the spread of drug resistance and prolonging the therapeutic life span of. Nevertheless, drug resistance of parasites to the respective partner drug is a matter of concern. Artesunate-amodiaquine (AQ) and artemether-lumefantrine (AL) are two registered fixed-dose artemisinin combination chemotherapies used in Africa which are GMP-manufactured at industrial scale. There is still limited data from randomised, controlled trials to support the general effectiveness of these two ACTs in Africa, including Ghana. More data is needed to compare these two therapies to make evidence-based first-line treatment decisions. Importantly, it is difficult to predict how combination therapy may affect the spread of drug resistance and monitoring drug resistance markers should be embedded in these trials to guide drug policy decision.
The aim of this open-labelled, randomised drug trial is to compare the effectiveness and safety of artesunate-amodiaquine (Arsucam®) against artemether plus lumefantrine (Coartem®) for the treatment of children under five years of age with uncomplicated Plasmodium falciparum malaria.
Eligibility| Ages Eligible for Study: | 6 Months to 59 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female outpatients aged 6 months to 59 months
- Absence of severe malnutrition
- A slide-confirmed P. falciparum asexual parasitaemia between 2,000/µl and 200,000/µl
- A measured axillary temperature ≥ 37.5 °C or rectal/tympanic temperature ≥ 38.0 °C
- Absence of general danger signs (unable to drink; repeated vomiting; recent history of convulsions; lethargic or unconscious state; unable to stand up or to sit)
- Ability to tolerate oral therapy
- Permanent residence in study area
- Informed consent by the legal representative of the subject, if possible, the parents
Exclusion Criteria:
- Adequate anti-malarial treatment within the previous 7 days
- Antibiotic treatment for a current infection
- Previous participation in a clinical trial
- Haemoglobin < 5 g/dl
- Leucocyte count: > 15000/µl
- Mixed plasmodial infection
- Severe malaria as defined by WHO recommendations
- Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection) or concomitant disease masking assessment of response
- History of allergy or intolerance against trial medication
Contacts and Locations| Ghana | |
| Agogo Presbyterian Hospital | |
| Agogo, Asante Akim North District, Ghana | |
| Principal Investigator: | Daniel Ansong, MD | School of Medical Science (SMS), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00374205 History of Changes |
| Other Study ID Numbers: | 01KA22062006 |
| Study First Received: | September 8, 2006 |
| Last Updated: | November 26, 2007 |
| Health Authority: | Ghana: Ministry of Health Germany: Ethics Commission |
Keywords provided by Bernhard Nocht Institute for Tropical Medicine:
|
Ghana Effectiveness Safety Drug-Resistance |
ACT Coartem Arsucam |
Additional relevant MeSH terms:
|
Malaria Malaria, Falciparum Protozoan Infections Parasitic Diseases Amodiaquine Artemether Artemisinins Artesunate Lumefantrine Artemether-lumefantrine combination Antimalarials |
Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antifungal Agents Coccidiostats Schistosomicides Antiplatyhelmintic Agents Anthelmintics Amebicides |
ClinicalTrials.gov processed this record on May 23, 2013